Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hematopoietic stem cells carrying Philadelphia (Ph) chromosome and the oncogenic BCR-ABL1 fusion gene. microRNAs (miRNAs) belong to hematopoiesis transcription regulators and their deregulated expression associates with pathogenesis of CML. The current study assesses and validates expression profiles of selected oncogenic and tumor suppressing miRNAs that are associated with different imatinib mesylate (IM) response in CML patients carrying rare BCR-ABL variants. Microarray analysis has identified different expression of 70 miRNAs (46 up- and 24 down-regulated) when compared IM-resistant with IM-responsive patients carrying Ph chromosome. Significantly up-regulated expression of oncogenic miRNAs (miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155) and significantly down-regulated expression of tumor suppressing miRNAs (let-7d, miR-205, miR-320, miR-451 and miR-574) in IM-resistant compared to IM-responsive patients was confirmed and validated by qRT-PCR. This study confirms the involvement of the selected oncogenic and tumor suppressing miRNAs in CML pathogenesis and IM response and suggests that these miRNAs could be suitable biomarkers for differential diagnosis of CML patients carrying rare BCR-ABL transcripts, as well as for prediction of their IM response and therapy outcome.

Key words: miRNA, chronic myeloid leukemia, microarray, qRT-PCR, peripheral blood
molecular evidence of persisting disease have been observed in 20–25 % of IM-treated patients [4].

Molecular diagnostics of CML using qRT-PCR and nested PCR enables to confirm the BCR-ABL fusion gene and determines the number of BCR-ABL transcripts with very good correlation between blood and bone marrow samples. In 95% of CML cases, BCR-ABL fusion transcripts are b2a2 and b3a2 and these can be detected by qRT-PCR. In the rest of CML patients, rare b3a3, b2a3, c3a2, b1a1 and e1a3 or other variants are typical, but these are undetectable by routine diagnostic qRT-PCR and can only be revealed by non-quantitative PCR. These rare BCR-ABL variants occur in exceptional CML cases where BCR breakpoints are outside of the main defined cluster regions (major-M-BCR, minor–m-BCR or micro- mu-BCR), or with unusual breakpoints in ABL resulting in BCR-ABL transcripts with b2a3 or b3a3 junctions, or with aberrant fusion transcripts containing variable lengths of intronic sequence inserts. Different types of BCR-ABL rearrangement are associated with different clinical course and prognosis and their frequency in population relates with different ethnic backgrounds [5,6]. Consequently, also the treatment outcomes are difficult to monitor. In such cases, microRNA (miRNA) expression profiling could provide reliable alternative diagnostic and predictive tool to confirm CML diagnosis and predict IM-resistance.

Chromosomal translocations are usually associated with amplification or deletion of regions carrying sequences encoding important regulatory molecules, including miRNAs. miRNAs are non-coding, small (20–25 nts) single-stranded RNA molecules that regulate the expression of genes involved in cell development, proliferation [7] and differentiation [8], apoptosis [9], immune response, inflammation [10], viral infection [11], and also in pathological states such as autoimmune, cancerous [12] and other diseases.

miRNAs have been shown to promote tumor growth acting both as oncogenes and tumor suppressors. Aberrant miRNA levels have been observed in many cancers, as compared to their normal tissue counterparts [13]. The first miRNA molecules associated with human leukemia pathogenesis have been found in chronic lymphocytic leukemia (CLL) [14]. Deletion of chromosome (13)(q14) in CLL has been linked to down-regulation of suppressors miR-15a and miR16 [14, 15]. In contrast, in B-cell lymphomas amplification of chromosome (13)(q31) is associated with overexpression of the oncogenic miRNA cluster 17–92 [16]. Although several deregulated miRNAs have already been associated with CML, some data is rather controversial and its relevant diagnostic and predictive value is still missing. Oncogenic miRNAs, miR-155, miR-17–92 cluster, miR-15a, miR-16, miR-142, miR-181, miR-221 and some others, have been described as crucial regulatory molecules associated with hematologic malignancies, including CML. Their deregulation has been observed in acute myeloid leukemia (AML), CLL, diffuse large B-cell lymphoma (DLBCL) [17–19], and in a number of leukemia and lymphoid cell lines [13, 15, 19–25]. In present study, we have focused on validation of the selected miRNAs identified as the most relevant for CML diagnosis confirmation and early IM response prediction. To achieve this, we employed a microarray platform to characterize the group of differentially expressed miRNAs in peripheral blood mononuclear cells from IM-resistant and IM-responsive patients carrying Ph chromosome. Of the group of differentially expressed miRNAs, we have further focused on up-regulated oncogenic miRNAs, miR-17–92 cluster (namely miR-17, miR-18a, and miR-20a), miR-21, miR-27a and miR-155, as well as on down-regulated tumor suppressing miRNAs, let-7d, miR-205, miR-320, miR-451 and miR-574. Expression profiles of these miRNAs were subsequently validated by qRT-PCR. We suggest that, in addition to well-known gene mutations and aberrations, deregulated expression profiles of these miRNAs can provide further molecular tool for CML diagnosis and therapy prediction. Hence, miRNA profiling can clinically be used for CML diagnosis, patient stratification, treatment response prediction and therapy outcome monitoring, especially in rare cases where conventional molecular diagnostics is not sufficient and/or is unable.

**Patients and methods**

**Patient samples.** Blood samples were obtained from 9 CML patients with detected Ph chromosome (Ph+ patients) and 14 healthy individuals in the Clinics of Hematology and Transfusion, University Hospital of Medical Faculty of Comenius University, and in National Institute for Oncology, Bratislava, Slovakia. The retrospective patient study identified BCR-ABL positive cases with fusion atypical transcripts – c3a2, b1a1, b3a3, b2a3 and e1a3. Selection of patients with rare BCR-ABL fusion transcripts explains the small cohort analyzed in this study. CML diagnosis was determined by conventional diagnostic methods. Patients were treated with imatinib mesylate (IM; dose 400mg/day) during 6 months. In this study, according to therapy outcome, 5 patients identified as IM-responsive and 4 patients as IM-resistant were further analyzed for miRNA expression profiles (Table 1). The study was approved by the scientific committee of the University Hospital of Medical Faculty of Comenius University.

**Table 1. IM-response and BCR-ABL variants of patients.**

<table>
<thead>
<tr>
<th>Patient</th>
<th>BCR-ABL variant</th>
<th>IM – response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>c3a2</td>
<td>resistant</td>
</tr>
<tr>
<td>2</td>
<td>b3a3</td>
<td>resistant</td>
</tr>
<tr>
<td>3</td>
<td>b3a3</td>
<td>resistant</td>
</tr>
<tr>
<td>4</td>
<td>b2a3</td>
<td>resistant</td>
</tr>
<tr>
<td>5</td>
<td>b2a3</td>
<td>responsive</td>
</tr>
<tr>
<td>6</td>
<td>b2a3</td>
<td>responsive</td>
</tr>
<tr>
<td>7</td>
<td>e1a3</td>
<td>responsive</td>
</tr>
<tr>
<td>8</td>
<td>b1a1</td>
<td>responsive</td>
</tr>
<tr>
<td>9</td>
<td>b3a3</td>
<td>responsive</td>
</tr>
</tbody>
</table>
University and National Institute for Oncology, Bratislava, Slovakia. All subjects donated their samples with informed consent approved by the Ethnic Committee of the Institute of Hematology and Blood Transfusion and each patient/donor gave written informed consent in accordance with the Declaration of Helsinki. Peripheral blood mononuclear cells were prepared by sedimentation using Ficoll-Paque™ PLUS (GE Healthcare, Freiburg, Germany) density gradient. Cells were suspended in freezing solution (DMEM supplemented with 10% DMSO and 20% fetal calf serum) and stored at -80 °C before RNA extraction.

**RNA extraction.** To extract total RNA containing all small RNA molecules including miRNAs, TRI Reagent solution (Life technologies), Ribopure-Blood kit (Ambion Inc., no. AM1928, Austin, TX, USA) and RNA/DNA/Protein Purification Kit (Norgen Biotek®, Thorold, ON, Canada) were used. Total RNA was quantified using the NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, USA) and the Qubit fluorimeter (Qubit® RNA HS Assay Kit, LifeTechnologies, USA). The RNA integrity was assessed using the Agilent 2100 bioanalyzer (Agilent, Palo Alto, CA, USA). Ribopure-Blood kit and RNA purification kit gave 230/280 ratio, and therefore were used for RNA extraction for microarrays. TRI Reagent RNA extraction was used for real-time qRT-PCR reactions.

**miRNA microarray profiling and data analysis.** miRNA expression profiling in patients’ samples performed using 100 ng of total RNA was processed using the Agilent miRNA Complete Labeling and Hyb Kit (5190-0456, Santa Clara, California, USA) according to the manufacturer’s protocol (version 2.4, September 2011) and recommendations. Briefly, after the dephosphorylation of the 3’ ends of RNA molecules, the Cyanine3-pCp was ligated to the 3’ end. Next, the samples were dried, suspended in the hybridization mix and loaded onto the Sureprint G3 UNRESTRICTED miRNA 8X60K slide (G4872A-04606). The loaded slide, placed in the Agilent Microarray Hybridization Chamber (G2534A), was incubated for 20 hrs at 55°C/20 rpm in the Agilent hybridization oven (G2545A). After washing with the Gene Expression Wash Buffers 1 and 2 (5188-5327), the washed and dried slide was scanned in the Innoscan 900 microarray scanner (Innopsys Inc., Carbone, France) with the resolution of 3 micrometers. The resulting images of individual arrays were extracted with the Mapix 7.3.0 software (Innopsys Inc., Carbone, France) and exported as GPR files.

GPR files were imported into the R workspace by the read.maimages() function in the limma package and transformed into the “uRNAList” format to enable use of functions from the R package „AgiMicroRna“; subsequently, without background subtraction, data were quantile-normalized between arrays by the function rnaMicroRna() in the AgiMicroRna package. Finally, standard limma procedure was applied to the normalized data to analyze differential expression between studied groups.

**miRNA qRT-PCR quantification.** Differentially expressed oncogenic miRNAs, miR-17, miR-18a, miR-20a, miR-21, miR-27a, miR-155, and tumor suppressing miRNAs, let-7d, miR-205, miR-320, miR-451 and miR-574, identified by miRNA microarray were further validated by qRT-PCR. Expression of mature miRNAs was determined using First-Strand cDNA Synthesis System (Central European Biosystems, Czech Republic) supplemented with poly(A)polymerase (Takara, Japan) and ATP (Sigma, Germany). Briefly, for cDNA synthesis 100 ng of RNA in a final volume of 10 μl including 1μl of 10x poly(A)polymerase buffer, 0.1 mM of ATP, 1μM of RT-primer, 0.1 mM of each deoxynucleotide (dATP, dCTP, dGTP and dTTP), 100 units of MuLV reverse transcriptase and 1 unit of poly(A)polymerase was incubated at 42°C for 1 hour followed by enzyme inactivation at 95°C for 5 minutes. The sequence of the oligo-d(T)/adapter primer was 5’-CAGGTCCAGTTTTTTTTTTTTTTTVN, where V is A, C and G and N is A, C, G and T (IDT, Leuven, Belgium).

Real-time PCR detection and quantification of mature forms of hsa-miR-17-5p, hsa-miR-18a-5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-27a-3p, hsa-miR-155-5p, hsa-let-7d-3p, hsa-miR-205-3p, hsa-miR-320-5p, hsa-miR-451-5p, hsa-miR-574-5p and small RNA reference endogenous controls Snord38B and Snord44 were performed using SYBR Premix Ex Taq II (Tli RNaseH Plus), ROX plus (Takara, Japan), adapter-specific reverse primer and miRNA-specific (and Snord-specific) forward primers (Utility model 6932 and Utility model applications PUV5039/2014-5045/2014). qPCR was performed using BIOER, LineGene 9660 Real-Time PCR System (Hangzhou Bioer Technology Co., Ltd., China) at following settings: 95°C for 5 min, followed by 40 cycles of 95°C for 20 sec and 60°C for 50 sec, followed by melt cycle. Mature miRNA amplification was done in triplicate. Ct values were averaged and normalized against reference endogenous controls Snord44 and/or Snord38B. Relative expression was determined by the 2^(-ΔΔCt) comparative threshold method.

**Statistical analysis.** The significance of fold change in miRNA expression was analyzed using the Wilcoxon signed rank test applied to the ΔCt values. miRNA differential expression analysis between unrelated samples was conducted using the 2-tailed Mann-Whitney U test. Analyses were performed using GraphPad Prism v.5 (La Jolla, CA, USA) and SAS v.9 (Cary, NC, USA) Software. Results with a P value <0.05 were considered significant.

**Results.**

Microarray miRNA expression profiles and IM-response. To decipher a potential miRNA expression signature associated with IM response in CML using a miRNA microarray, we have analyzed expression profiles of miRNAs of Ph+ IM-resistant patients and compared them with Ph+ patients who responded to drug. Microarray analysis identified 70 differently expressed miRNAs between IM-resistant and IM-responsive patients. The expression levels of miR-17, miR-18a, miR-19a, miR-20a (those of miR-17–92 cluster), miR-21, miR-27a and miR-155, have markedly been increased...
in IM-resistant compared to IM-responsive Ph+ patients. In addition, expression levels of miR-15a, miR-22, miR-26a/b, miR-29c, miR-93, miR-145, miR-150, miR-181a and miR-342 were moderately increased in IM-resistant Ph+ patients. Let-7b, d, miR-34b, miR-205, miR-320b, c, d, miR-451b and miR-574 were the most down-regulated miRNAs. Based on this data, all above expression profiles could potentially be used to differentiate IM-resistant from IM-responsive Ph+ patients (Figure 1A). Clustering analysis of expression of the selected oncogenic and tumor suppressing miRNAs differentially expressed between IM-resistant and IM-responsive Ph+ patients clearly separates both groups suggesting that this miRNA profile could distinguish the different IM-response in CML patients (Figure 1B).

**qRT-PCR validation.** In order to validate the microarray data and to ensure that the variations observed were not due to a technical issue, we have carried out SYBR Green miRNA specific qRT-PCR analyses. We focused on a group of the selected oncogenic miRNAs with altered expression between IM-resistant and IM-responsive Ph+ patients, miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155, as well as on tumor suppressors let-7d, miR-205, miR-320, miR-451 and miR-574. Expression of each miRNA was determined in IM-resistant and IM-responsive Ph+ patients and the data obtained was compared with that of healthy control individuals.

**Figure 1.** miRNA microarray expression profile and cluster analysis of IM-resistant against IM-responsive Ph+ patients. A) Log FC values showed up-regulation of oncogenes miR-17, miR-18a, miR-19a, and miR-20a of miR-17~92 cluster, next miR-21, miR-22, miR-27a, miR-26a, miR-29c, miR-93, miR-145, miR-155, miR-181a and miR-342, and down-regulation of tumor suppressors let-7, miR-34b, miR-205, miR-320b-d, miR451b and miR-574 in IM-resistant compared to IM-responsive Ph+ patients. Values represent mean ± SEM; n=4, * p<0.05. B) Cluster analysis confirmed differential expression of the selected miRNA oncogenes and tumor suppressors between IM-resistant and IM-responsive Ph+ patients. Shown is representative miRNA array heat map where miRNA expression profiles of 2 IM-resistant patients were compared with those of 4 IM-responsive patients. Performed Agilent miRNA arrays use the quantile normalization with no background subtraction (transformation), as recommended by manufacturer (light grey scale – down-regulated expression, dark grey/black scale up-regulated expression).

**Figure 2.** Real-time RT-PCR validation of the selected oncogenic miRNAs. The expression of miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155 was significantly up-regulated in IM-resistant Ph+ patients (n=4, 3 replicates each, dark grey columns) compared to healthy individuals (n=14, 3 replicates each, white columns). Values represent mean ± SEM; * p<0.05, **p<0.01. Significant increase of expression was observed in individual miRNAs between IM-resistant (n=4, 3 replicates each, dark grey columns) and IM-responsive Ph+ patients (n=5, 3 replicates each, light grey columns). Values represent mean ± SEM; # p<0.05, ##p<0.01. All data were normalized against Snord44 reference gene expression control.
qRT-PCR differential analysis of miRNA expression in IM-resistant Ph+ patients compared to healthy individuals confirmed significantly increased expression levels of selected miRNAs, miR-17 (5.8-fold), miR-18a (4.6-fold), miR-20a (5.1-fold), miR-21 (1.7-fold), miR-27a (2.3-fold) and miR-155 (2.0-fold), when normalized against endogenous reference gene expression control Snord44 (Figure 2). Significant increase of expression of miR-17 (3.8-fold), miR-18a (1.4-fold), miR-20a (2.7-fold), miR-21 (2.4-fold), miR-27a (4.0-fold) and miR-155 (2.3-fold) was also observed in IM-resistant Ph+ patients when compared with Ph+ IM-responsive ones (Figure 2). Similarly, significant up-regulation was confirmed when IM-resistant patients were compared to IM-responsive Ph+ patients and data was normalized against different endogenous reference gene expression control Snord38. The observed increase of expression of individual miRNAs was following: miR-17 (3.1-fold), miR-18a (1.5-fold), miR-20a (2.6-fold), miR-21 (2.7-fold), miR-27a (2.7-fold) and miR-155 (2.5-fold) (Figure 3).

On the other hand, all selected tumor suppressing miRNAs except miR-451 (showing only decreasing tendency) were significantly down-regulated after IM treatment in IM-resistant compared to IM-sensitive Ph+ patients: let-7d (2.4-fold), miR-205 (1.9-fold), miR-20 (2.6-fold), miR-451 (1.1-fold) and miR-574 (2.4-fold). Obtained data were normalized against Snord44 endogenous reference gene expression control (Figure 4).

Surprisingly, when these miRNAs were compared against healthy controls both IM-responsive and -resistant patients
expressed up-regulated levels of miR-205 (5-fold in responsive, 4.7-fold in resistant), miR-320 (3.1-fold in responsive, 1.1-fold in resistant) and miR-574 (6.2-fold in responsive, 2.2-fold in resistant), although the levels of these miRNAs were significantly higher in IM-responsive compared to -resistant patients. Expression levels of let-7d and miR-451 were unaffected (Figure 5).

In IM-responsive patients, IM treatment down-regulated expression levels of oncogenic miRNAs and up-regulated tumor suppressing miRNAs, while in IM-resistant patients the expression levels of oncogenic and tumor suppressing miRNAs stayed significantly increased and decreased respectively, even after 6 months of therapy.

Discussion

The current CML treatments include hydroxyurea, bone marrow transplantation or tyrosine kinase inhibitors (TKI). IM is commonly used highly effective TKI in CML treatment; however, IM resistance and intolerance remain a major clinical problem. 20-25% of CML patients is resistant to IM or develops resistance during the treatment. The IM resistance may occur due to BCR-ABL amplification, overexpression or spontaneous mutations in tyrosine kinase domain of BCR-ABL. Resistance to IM may also develop due to evolution of the disease with the occurrence of rare or novel cytogenetic aberrations leading to BCR-ABL independent proliferation of leukemic cells [26]. Regular monitoring of patients’ resistance and practical monitoring of IM response can be used to guide treatment choice and provide patients with significantly better long-term outcomes. To predict and manage IM resistance, multiple potential biomarkers are intensively being searched. Recognition of IM intolerance and resistance, as well as monitoring of treatment outcomes, becomes even more difficult if patients carry rare variants of the BCR-ABL fusion gene. In our study, we have compared miRNA expression profiles in small cohort of IM-resistant and IM-responsive CML patients carrying Ph chromosome with rare BCR-ABL variants to identify additional molecular markers reflecting and predicting resistance to IM in these patients.

Microarray comparison of miRNA expression in peripheral blood of Ph+ patients resistant to IM and Ph+ patients responsive to this drug revealed 70 differentially expressed miRNAs, preferentially oncomirs (miR-15a, miR-17, miR-18a, miR-20a, miR-21, miR-22, miR-26a, miR-27a, miR-29c, miR-93, miR-145, miR-150, miR-155, miR-181a and miR-342) and several tumor suppressors (let-7, miR-34b, miR-205, miR-320, miR-451 and miR-574). Of set of differentially expressed miRNAs, we further validated 6 up-regulated oncogenic miRNAs and 5 down-regulated suppressors that have been shown to be highly associated with pathogenesis of several hematological malignancies, including CML [17, 18].

Subsequently, significant up-regulation of these 6 oncomirs (miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155) and down-regulation of 5 tumor suppressing miRNAs (let-7, miR-205, miR-320, miR-451b and miR-574) have been validated by qRT-PCR. Both microarray and qRT-PCR validation confirmed that miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155 are significantly up-regulated and let-7, miR-205, miR-320, and miR-574 are significantly down-regulated in IM-resistant compared to IM-responsive Ph+ patients. However, significant down-regulation of miR-451 was not confirmed by qRT-PCR, probably due to small cohort. Significantly different expression profiles of these miRNAs can distinguish IM-resistant form IM-responsive CML patients carrying rare BCR-ABL transcripts.

miR-155 has been described to be overexpressed in many hematological malignancies [27, 28], being considered as a regulator of myelopoiesis [29]. However, its expression in CML remains rather controversial. Observed up-regulation of miR-155 in IM-resistant patients but not in IM-responsive patients seems to be in correlation with data of Rokah and co-authors [3] who detected down-regulation of miR-155 in chronic myeloid cells and CML patients. Overexpressed miR-17–92 cluster plays an oncogenic role in CML, being regulated by c-MYC. BCR-ABL fusion gene induces expression of c-MYC and consequently up-regulates the cluster expression [30]. The miR-17–92 cluster contributes to proliferation and inhibition of apoptosis via E2F1 (E2F transcription factor 1), PTEN (phosphatase and tensin) and BIM (BCL2-interacting mediator of cell death) transcription factors; namely miR-17 and miR-20a has been described to inhibit pro-apoptotic BIM and subsequent mitochondria-dependent apoptosis [31]. Apoptotic and proliferative signals of c-MYC and E2F1 are tightly balanced by the expression of the miR-17–92 cluster [32-34]. In evolution, strongly conserved miR-21 has been found to be associated with a variety of neoplastic disorders targeting a number of tumor suppressor genes widely involved in growth, apoptosis, invasion and cell cycle (e.g. programmed cell death 4 [PDCD4], PTEN, tropomyosin [TPM1], etc.) [35, 36]. Knock-down of endogenous miR-21 expression contributed to sensitizing leukemic K562 cells to therapy mainly through increasing apoptosis [37]. Although overexpressed miR-21 is one of the most prominent miRNAs implicated in the tumor growth, proliferation, anti-apoptosis and response to chemotherapy, its role has rarely been characterized and studied with regard to CML [38]. miR-27a is an important regulator of hematopoietic development as it targets the 3’ UTR of RUNX1 transcription factor, a master regulator in hematopoietic development [39]. Up-regulated miR-27a in cooperation with miR-17~92 cluster inhibits the RUNX1 and directly activates PU.1 and CEBPA (CCAAT/ enhancer-binding protein alpha), transcription factors critical for determination of the myeloid and lymphoid lineage from hematopoietic precursors [40-42]. Increased miR-27a also promotes angiogenesis [40] and can alter the activity of NF-kB, MAPKs/p38, c-Jun and ERK.

In correlation with published data, we have also observed down-regulation of typical tumor suppressing miRNAs: let-7, miR-34 and miR-200 families [43, 44]. Several studies have re-
ported that down-regulation of tumor suppressing miRNAs is involved in regulation of apoptosis, epithelial to mesenchymal transition (EMT) and tumor invasion in association with CML and other hematological malignancies [23, 45-47]. Observed down-regulated miR-320 via posttranscriptional repression of TR–1 (transferrin receptor-1) affects cell growth modulation iron availability, and targets other proteins necessary for cell growth and proliferation [48]. Down-regulated miR-451 and miR-547 are considered potent suppressors of oncogenesis that have been reported to target several signaling pathways [37, 49]. miR-451 together with miR-27a has been described to modulate multidrug resistance by targeting BCL2 and MDR1, respectively [50].

According to our results that are in line with observations of other authors, we suggest that oncogenic miRNAs, miR-155, miR17~92 cluster together with miR-21 and miR-27a, and tumor suppressing miRNAs, let-7, miR-205, miR-320, miR-451 and miR-574, could represent a suitable group of biomarkers relevant for early detection of IM-resistance and CML pathophysiology. Thus, these selected miRNAs represent novel molecular biomarkers offering additional molecular diagnostic and predictive tool enabling efficient monitoring of treatment response and therapy outcomes in a group of CML patients with rare BCR-ABL variants. Undoubtedly, to confirm predictive potential of identified miRNA biomarkers, these should thereto be examined in samples from patients with rare BCR-ABL variants before receiving a therapy. Such experiments are to be carried out in the laboratory in near future.

Acknowledgements: This work was supported by grant co-sponsored by sources of EU – European fund for regional development through operation program of Research and Development (project code ITMS 26240220074/call code OPVaV-2011/4.2/07-SORO). We would like to greatly acknowledge personnel of University Hospital of Medical Faculty, Comenius University and National Institute for Oncology, in Bratislava, Slovakia for their contribution and help with patients’ samples collection and management.

References


[18] RINALDI A, PORETTI G, KWEE I, ZUCCA E, CATA- 

[19] KLUIVER J, POPPEMA S, DE JONG D, BLOKZIJK T, 


[22] O’CONNELL RM, RAO DS, CHAUDHURI AA, BOLDIN 

[23] THOMPSON RC, HERSCOVITCH M, ZHAI O, FORD TJ, 


[25] POSPIŠIL V, VARGOVA K, KOKAVEC J, RYBAROVA J, 
SAVVULIDI F et al. Epigenetic silencing of the oncogenic miR-17–92 cluster during PU.1-directed macrophage differentiation. The EMBO journal 2011; 30: 4450–4464. [http://dx.doi.org/10.1038/emboj.2011.317]

[26] HOCHHAUS A, KREIL S, CORBIN AS, LA ROSEE P, 
MÜLLER MC et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196. [http://dx.doi.org/10.1038/sj.leu.2402741]


[28] JURKOVICOVA D, MAGYERKOVA M, KULCSAR I, KRIV 

[29] FARAOANIA I, ANTONETTI FR, CARDONE J, BONMAS 

B, HOCHHAUS A et al. Expression of the miR-17–92 polycis-


[32] O’DONNELL KA, WENTZEL EA, ZELLER KI, DANG 


[37] LI X, SANDA T, LOOK AT, NOVINA CD, VON BOEHMER 


[44] JONGEN-LAVRENCIC M, SUN SM, DIJKSTRA MK, VALK 
PJ, LOWENBERG B. MicroRNA expression profiling in rela-